Overview

Chemotherapy Plus Gefitinib Followed by Chemotherapy, Radiation Therapy, and Gefitinib For Head and Neck Cancer

Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
Although gefitinib has been combined successfully with various chemotherapeutic regimens with minimal increase in overall toxicity, experience with concurrent radiation therapy is limited. In this trial, we will evaluate the feasibility, toxicity, and effectiveness a novel combination of chemotherapy, radiation therapy, and gefitinib.
Phase:
Phase 2
Details
Lead Sponsor:
SCRI Development Innovations, LLC
Collaborators:
AstraZeneca
Aventis Pharmaceuticals
Treatments:
Carboplatin
Docetaxel
Fluorouracil
Gefitinib